Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes

Nature Genetics

Volumn 39, Issue 8, 2007, Pages 969-976

  Kassmann, Celia M ^a   Lappe Siefke, Corinna ^a   Baes, Myriam ^b   Brügger, Britta ^c   Mildner, Alexander ^d   Werner, Hauke B ^a   Natt, Oliver ^e   Michaelis, Thomas ^e   Prinz, Marco ^d   Frahm, Jens ^e   Nave, Klaus Armin ^a  

^a MAX PLANCK INSTITUTE OF EXPERIMENTAL MEDICINE   (Germany)

^b DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATAXIA; B LYMPHOCYTE; BRAIN CELL; BRAIN DAMAGE; CD8+ T LYMPHOCYTE; CELL LOSS; CELL SURVIVAL; CONTROLLED STUDY; DEMYELINATING DISEASE; DEMYELINATION; GLIA CELL; LIPID METABOLISM; LIPOGENESIS; LYMPHOCYTIC INFILTRATION; MOUSE; NERVE FIBER DEGENERATION; NEURITIS; NEUROPROTECTION; NONHUMAN; OLIGODENDROGLIA; PEROXISOME; PRIORITY JOURNAL;

ANIMALS; AXONS; CD8-POSITIVE T-LYMPHOCYTES; DEMYELINATING DISEASES; HUMANS; LIPID METABOLISM; MICE; NERVE FIBERS, MYELINATED; OLIGODENDROGLIA; PEROXISOMES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; T-LYMPHOCYTE SUBSETS;

MUS;

EID: 34547527078     PISSN: 10614036     EISSN: 15461718     Source Type: Journal    
DOI: 10.1038/ng2070     Document Type: Article

References (50)

1. Lazzarini, R.A. Myelin Biology and Disorders (Elsevier Academic, San Diego, California, USA, 2004).
2. Bjartmar, C. & Trapp, B.D. Axonal and neuronal degeneration in multiple sclerosis: mechanisms and functional consequences. Curr. Opin. Neurol. 14, 271-278 (2001).
3. Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278-285 (1998).
4. Griffiths, I. et al. Axonal swellings and degeneration in mice lacking the major proteolipid of myelin. Science 280, 1610-1613 (1998).
5. Lappe-Siefke, C. et al. Disruption of Cnp1 uncouples oligodendroglial functions in axonal support and myelination. Nat. Genet. 33, 366-374 (2003).
6. Suter, U. & Scherer, S.S. Disease mechanisms in inherited neuropathies. Nat. Rev. Neurosci. 4, 714-726 (2003).
7. Edgar, J.M. et al. Oligodendroglial modulation of fast axonal transport in a mouse model of hereditary spastic paraplegia. J. Cell Biol. 166, 121-131 (2004).
8. Ferreirinha, F. et al. Axonal degeneration in paraplegin-deficient mice is associated with abnormal mitochondria and impairment of axonal transport. J. Clin. Invest. 113, 231-242 (2004).
9. Schrader, M. & Fahimi, H.D. Mammalian peroxisomes and reactive oxygen species. Histochem. Cell Biol. 122, 383-393 (2004).
10. Wanders, R.J. Peroxisomes, lipid metabolism, and peroxisomal disorders. Mol. Genet. Metab. 83, 16-27 (2004).
11. Baes, M. et al. A mouse model for Zellweger syndrome. Nat. Genet. 17, 49-57 (1997).
12. Hirrlinger, J., Resch, A., Gutterer, J.M. & Dringen, R. Oligodendroglial cells in culture effectively dispose of exogenous hydrogen peroxide: comparison with cultured neurones, astroglial and microglial cells. J. Neurochem. 82, 635-644 (2002).
13. Gould, S.J. & Collins, C.S. Opinion: peroxisomal-protein import: is it really that complex? Nat. Rev. Mol. Cell Biol. 3, 382-389 (2002).
14. Dodt, G. et al. Mutations in the PTS1 receptor gene, PXR1, define complementation group 2 of the peroxisome biogenesis disorders. Nat. Genet. 9, 115-125 (1995).
15. Baes, M., Dewerchin, M., Janssen, A., Collen, D. & Carmeliet, P. Generation of Pex5-loxP mice allowing the conditional elimination of peroxisomes. Genesis 32, 177-178 (2002).
16. Chang, C.C. et al. Metabolic control of peroxisome abundance. J. Cell Sci. 112, 1579-1590 (1999).
17. Saher, G. et al. High cholesterol level is essential for myelin membrane growth. Nat. Neurosci. 8, 468-475 (2005).
18. Zoeller, R.A. & Raetz, C.R. Isolation of animal cell mutants deficient in plasmalogen biosynthesis and peroxisome assembly. Proc. Natl. Acad. Sci. USA 83, 5170-5174 (1986).
19. Rodemer, C. et al. Inactivation of ether lipid biosynthesis causes male infertility, defects in eye development and optic nerve hypoplasia in mice. Hum. Mol. Genet. 12, 1881-1895 (2003).
20. Moser, H.W., Bergin, A. & Cornblath, D. Peroxisomal disorders. Biochem. Cell Biol. 69, 463-474 (1991).
21. Wanders, R.J. & Waterham, H.R. Peroxisomal disorders I: biochemistry and genetics of peroxisome biogenesis disorders. Clin. Genet. 67, 107-133 (2005).
22. Forss-Petter, S. et al. Targeted inactivation of the X-linked adrenoleukodystrophy gene in mice. J. Neurosci. Res. 50, 829-843 (1997).
23. Lu, J.F. et al. A mouse model for X-linked adrenoleukodystrophy. Proc. Natl. Acad. Sci. USA 94, 9366-9371 (1997).
24. Kobayashi, T., Shinnoh, N., Kondo, A. & Yamada, T. Adrenoleukodystrophy protein-deficient mice represent abnormality of very long chain fatty acid metabolism. Biochem. Biophys. Res. Commun. 232, 631-636 (1997).
25. Simpson, J.E., Newcombe, J., Cuzner, M.L. & Woodroofe, M.N. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. J. Neuroimmunol. 84, 238-249 (1998).
26. McManus, C. et al. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. J. Neuroimmunol. 86, 20-29 (1998).
27. Loers, G., Aboul-Enein, F., Bartsch, U., Lassmann, H. & Schachner, M. Comparison of myelin, axon, lipid, and immunopathology in the central nervous system of differentially myelin-compromised mutant mice: a morphological and biochemical study. Mol. Cell. Neurosci. 27, 175-189 (2004).
28. Genoud, S. et al. Notch1 control of oligodendrocyte differentiation in the spinal cord. J. Cell Biol. 158, 709-718 (2002).
29. Schrader, M. & Fahimi, H.D. Peroxisomes and oxidative stress. Biochim. Biophys. Acta 1763, 1755-1766 (2006).
30. Loes, D.J. et al. Analysis of MRI patterns aids prediction of progression in X-linked adrenoleukodystrophy. Neurology 61, 369-374 (2003).
31. Wilken, B. et al. Quantitative proton magnetic resonance spectroscopy of children with adrenoleukodystrophy before and after hematopoietic stem cell transplantation. Neuropediatrics 34, 237-246 (2003).
32. Dubois-Dalcq, M., Feigenbaum, V. & Aubourg, P. The neurobiology of X-linked adrenoleukodystrophy, a demyelinating peroxisomal disorder. Trends Neurosci. 22, 4-12 (1999).
33. Mosser, J. et al. Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters. Nature 361, 726-730 (1993).
34. Kemp, S. & Wanders, R.J. X-linked adrenoleukodystrophy: Very long-chain fatty acid metabolism, ABC half-transporters and the complicated route to treatment. Mol. Genet. Metab. 90, 268-276 (2007).
35. Pujol, A. et al. Late onset neurological phenotype of the X-ALD gene inactivation in mice: a mouse model for adrenomyeloneuropathy. Hum. Mol. Genet. 11, 499-505 (2002).
36. Hudspeth, M.P. & Raymond, G.V. Immunopathogenesis of adrenoleukodystrophy: current understanding. J. Neuroimmunol. 182, 5-12 (2006).
37. Barth, P.G. et al. Late onset white matter disease in peroxisome biogenesis disorder. Neurology 57, 1949-1955 (2001).
38. Baumgartner, M.R. et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann. Neurol. 44, 720-730 (1998).
39. + T cells in multiple sclerosis and its animal models. Curr. Drug Targets Inflamm. Allergy 4, 239-245 (2005).
40. Barnett, M.H. & Prineas, J.W. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55, 458-468 (2004).
41. Raivich, G. et al. Immune surveillance in the injured nervous system: T-lymphocytes invade the axotomized mouse facial motor nucleus and aggregate around sites of neuronal degeneration. J. Neurosci. 18, 5804-5816 (1998).
42. Ip, C.W. et al. Immune cells contribute to myelin degeneration and axonopathic changes in mice overexpressing proteolipid protein in oligodendrocytes. J. Neurosci. 26, 8206-8216 (2006).
43. Natt, O. et al. High-resolution 3D MRI of mouse brain reveals small cerebral structures in vivo. J. Neurosci. Methods 120, 203-209 (2002).
44. Gallyas, F. Silver staining of myelin by means of physical development. Neurol. Res. 1, 203-209 (1979).
45. Bielschowsky, M. Die Silberimprägnation der Neurofibrillen. J. Psychol. Neurol. 3, 169-183 (1904).
46. Jung, M., Sommer, I., Schachner, M. & Nave, K.A. Monoclonal antibody O10 defines a conformationally sensitive cell-surface epitope of proteolipid protein (PLP): evidence that PLP misfolding underlies dysmyelination in mutant mice. J. Neurosci. 16, 7920-7929 (1996).
47. Norton, W.T. & Poduslo, S.E. Myelination in rat brain: method of myelin isolation. J. Neurochem. 21, 749-757 (1973).
48. Bligh, E.G. & Dyer, W.J. A rapid method of total lipid extraction and purification. Can. J. Biochem. Physiol. 37, 911-917 (1959).
49. Koivusalo, M., Haimi, P., Heikinheimo, L., Kostiainen, R. & Somerharju, P. Quantitative determination of phospholipid compositions by ESI-MS: effects of acyl chain length, unsaturation, and lipid concentration on instrument response. J. Lipid Res. 42, 663-672 (2001).
50. Gutcher, I., Urich, E., Wolter, K., Prinz, M. & Becher, B. Interleukin 18-independent engagement of interleukin 18 receptor is required for autoimmune inflammation. Nat. Immunol. 7, 946-953 (2006).